Active Ingredient History

  • Now
Voglibose is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Vogilbose was discovered in 1981, and was first launched in Japan in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.   Wikipedia

  • SMILES: OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
  • Mol. Mass: 267.28
  • ALogP: -4.49
  • ChEMBL Molecule:
More Chemistry
3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-c-(hydroxymethyl)-d-epi-inositol | a-71100 | ao 128 | ao-128 | basen | epi-inositol, 2,3-dideoxy-2-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-4-c-(hydroxymethyl)- | glustat | n-(1,3-dihydroxy-2-propyl)valiolamine | voglibose | voglistat


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue